Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) announced that its article on the results of the SPANGOPIX-01 clinical trial of pegfosimer manganese (SN132D) for contrast-enhanced MRI of breast cancer has been accepted for publication in the September 2025 issue of the peer-reviewed journal Investigative Radiology.
According to Spago, the article, titled “Safety, Tolerability, Efficacy and Pharmacokinetics of Pegfosimer manganese (SN132D) for Contrast Enhanced MRI of Breast Cancer,” highlights results from the SPANGOPIX-01 study, in which the product candidate demonstrated acceptable safety and clinically relevant contrast enhancement in MRI of primary tumors in patients with breast cancer.
Spago’s SpagoPix development program, featuring pegfosimer manganese (SN132D), aims to enhance the precision of MRI for suspected cancers and endometriosis by offering a selective contrast agent for more accurate visualization of tumors and other lesions.
Mats Hansen, CEO of Spago, commented, “A publication in one of the leading scientific journals in the medical imaging field is a strong validation of the extensive clinical development work behind the SpagoPix program. The publication also supports our ongoing business development work aimed at finding potential partners or other solutions for further development of the program.”
